HLA-C and cancer: Despite the need for a high-throughput sequencing method and bioinformatics algorithms to predict peptide binding to major histocompatibility complex (MHC) molecules, these antigens offer personalized approaches to cancer treatment and are under investigation in multiple clinical trials (ClinicalTrials.gov: NCT03552718, NCT03639714, NCT03953235, and NCT04147078).